Concord Biotech Plummets: Shares crashed 27% by Feb 14, capping a brutal week after a failed trial sank hopes—smallcap biotech’s reeling. Economic Times calls it a market overreaction; X debates if it’s a buying dip. Read more
Pharma M&A Heats Up: EY’s Feb 14 report highlighted a shift to smaller, smarter pharma deals—2025’s off to a cautious start. Big players like Pfizer are nibbling at agile biotechs—strategic or just safe? Read more
MedTech Wearable Tease: Fitbit unveiled a cardiac sensor Feb 14 with real-time AFib alerts—docs see potential, but privacy concerns linger. MedTech’s wearable race accelerates; will it stick? Read more
Quick Take: Feb 14’s biotech bust, pharma deals, and MedTech tease pull the sector in all directions—volatility reigns.
